Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
04. November 2024 07:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren /...
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients
01. November 2024 07:00 ET
|
Memo Therapeutics AG
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections...
Biotech company Eradivir is developing lead drug EV25 to treat influenza
09. Juli 2024 14:24 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08. Juli 2024 07:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08. Juli 2024 02:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
06. Dezember 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge...
Anti-Viral Therapies Market Growth ($82.92 Billion by 2028) Driven by Branded Drugs Segment during (2022-2028) – Global Report by The Insight Partners
09. März 2023 08:46 ET
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28. Juni 2021 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
03. Juni 2020 13:25 ET
|
Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex
14. April 2020 11:00 ET
|
Guardion Health Sciences, Inc.
- acuMMUNE now available for sale in the United States through online platforms - San Diego, California, April 14, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the...